Bertis, a South Korean proteomics-based precision medicine technology company, has established a US-based wholly-owned entity to expand its global presence. The subsidiary, called Bertis Bioscience, aims to establish a San Diego-based CLIA-certified lab facility in early Q4, 2022. It will offer proteomics-based screening and diagnostic tests, as well as an analysis platform to integrate multi-omics […]